<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92336">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01812954</url>
  </required_header>
  <id_info>
    <org_study_id>PSO-GOE</org_study_id>
    <secondary_id>50310</secondary_id>
    <nct_id>NCT01812954</nct_id>
  </id_info>
  <brief_title>Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jochen Schmitt.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universit√§t Dresden</source>
  <oversight_info>
    <authority>Germany: Federal Ministry of Education and Research</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is health economic analysis of medicinal treatment options for moderate-to-severe
      psoriasis vulgaris from the societal perspective. Efficacy data and other clinical outcomes
      will be derived from an up-to-date meta-analysis of randomized clinical trials (RCTs) for
      moderate-to-severe psoriasis. Direct and indirect costs will be extracted from various
      different sources, including summary of product characteristics (SPCs) and the German S3
      guideline on psoriasis care, health care utilization data and official statistics.

      The study aims to investigate the comparative cost-effectiveness of biologic and
      conventional systemic treatments currently (as of June 1st, 2012) approved for
      moderate-to-severe plaque-type psoriasis in Germany. Effectiveness will be measured by means
      of the pooled (Psoriasis Area and Severity Index) PASI-75 response rates as reported in RCTs
      Direct cost as well as indirect cost will be considered.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Cost per quality-adjusted life year (QALY) gained through treatment with each individual agent compared to supportive care as well as compared to placebo</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Psoriasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporins</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fumaric acid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acitretin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with moderate-to-severe psoriasis, who require systemic treatment to adequately
        control the disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -diagnosis of moderate-to-severe psoriasis

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jochen Schmitt, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Dresden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Denise B Kuester</last_name>
    <phone>+49351458</phone>
    <phone_ext>6499</phone_ext>
    <email>denise.kuester@uniklinikum-dresden.de</email>
  </overall_contact>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 25, 2013</lastchanged_date>
  <firstreceived_date>March 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dresden University of Technology</investigator_affiliation>
    <investigator_full_name>Jochen Schmitt.</investigator_full_name>
    <investigator_title>Director of Center for evidence-based healthcare</investigator_title>
  </responsible_party>
  <keyword>moderate-to-severe psoriasis</keyword>
  <keyword>cost utility analysis</keyword>
  <keyword>cost effectiveness analysis</keyword>
  <keyword>systemic treatment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>TNFR-Fc fusion protein</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Acitretin</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
